

Review of: "Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients"

Janette Furuzawa-Carballeda

Potential competing interests: No potential competing interests to declare.

The manuscript that compares the treatment between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients is fascinating since both therapies have shown to have efficacy for the hyperinflammatory phase of COVID-19.

However, some issues remain to be clarified to contextualize the compared data:

2. Define what is the primary and secondary outcome
3. What does mean the improvement in the table?
4. What was the baseline treatment of the patients?
5. Has any patient received dexamethasone or another corticosteroid before and during the study? For how long?
6. How many patients in each group were hospitalized? For how long?
7. How many patients required supplemental oxygen, and for how long?
8. How many patients in each group were diagnosed with hypertriglyceridemia, dyslipidemia, or diabetes?
9. Did all the patients complete the treatment?
10. What were the selection criteria of the original studies?
11. How many trials were open, how many were blind, and how many were randomized and placebo-controlled?
12. What statistical analysis was used to compare the publications?
13. Please express the data in the table as means \pm SD/SEM, median, and range.
14. Please review the statistics in the table since, by the Fisher exact test analysis, there are no differences between the groups concerning sex, hypertension, obesity, and mortality.
15. Please include the next study population:

Castro-Rocha A. Safety and efficacy of Fibroquel® (polymerized type I collagen) in adult outpatients with moderate COVID-19: an open-label study. *J Anesth Crit Care Open Access*. 2021;13(2):101–108.